This is a working overview of pentadecapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
The liver is grossly divided into two parts when viewed from above – a right and a left lobe – and four parts when viewed from below (left, right, caudate, and quadrate lobes). The falciform ligament makes a superficial division of the liver into a left and right lobe. From below, the two additional lobes are located between the right and left lobes, one in front of the other. A line can be imagined running from the left of the vena cava and all the way forward to divide the liver and gallbladder into two halves. This line is called Cantlie's line. Other anatomical landmarks include the ligamentum venosum and the round ligament of the liver, which further divide the left side of the liver in two sections. An important anatomical landmark, the porta hepatis, divides this left portion into four segments, which can be numbered starting at the caudate lobe as I in an anticlockwise manner. From this parietal view, seven segments can be seen, because the eighth segment is only visible in the visceral view.
hydrogen bond A form of electrostatic interaction between an electronegative atom and a hydrogen atom bound to a second electronegative atom. Hydrogen bonding is unique because the small size of the hydrogen atoms permits proximity of the interacting electrical charges, and may occur as an intermolecular or intramolecular force.
=== June === 1 June – A bioRxiv preprint reports the first use of base editing to alter the genome of early human embryos. Researchers at Columbia University used the technique to introduce precise single-letter DNA changes without the large chromosomal alterations previously associated with double-strand-break CRISPR gene editing, while noting that the approach remains far from clinical use and raises ethical questions over human germline engineering. 3 June – A report by the United Nations University Institute for Water, Environment and Health estimates that global data centre electricity consumption could reach 945 TWh by 2030, driven partly by growing demand for artificial intelligence, with associated water use rising to 9.3 trillion litres and carbon dioxide emissions to 399 million tonnes. 4 June – Chinese researchers discover the two-state model of liquid water theorizing that water is composed of two distinct and interconvertible local structures at the high and low density phase boundary. 5 June – Researchers at the University of Cambridge and DIOSynVax report the first human clinical trial of a vaccine whose active component was designed entirely by computer simulations. The candidate pan-Sarbecovirus vaccine, pEVAC-PS, uses a machine-learning-designed "super-antigen"; a phase I trial in 39 healthy volunteers finds it safe and able to trigger immune responses to SARS-CoV-2, SARS-CoV-1, and related bat coronaviruses.
=== 2020s === During the COVID-19 pandemic, the company was one of the major developers and processors of COVID-19 testing. In March 2020, Labcorp received emergency use authorization from the FDA for a test for SARS-CoV-2. In April 2020, the company developed the first COVID-19 test in which people were able to collect a sample at home. In July 2020, the company was processing 165,000 COVID-19 tests per day. In December 2021, the company acquired Toxikon, a contract research organization developing non-clinical testing services. In February 2022, the company acquired Personal Genome Diagnostics and its liquid biopsy and tissue-based genomic product, for $450 million in cash plus a possible earn-out of an additional $125 million. Also in February 2022, Labcorp entered into agreements with Ascension, one of the nation’s largest Catholic and nonprofit health systems, to manage Ascension's hospital-based laboratories in ten states and purchase assets of the health system's outreach laboratory business. In June 2023, Labcorp completed the corporate spin-off of Fortrea. In August 2024, Labcorp acquired the assets of bankrupt Invitae for $234 million. In December 2025, Labcorp acquired the ambulatory lab businesses from Community Health Services (CHS) in 13 states for $194 million. In January 2026, it was announced that Labcorp had sold select assets of its early development medical device testing business to NAMSA, a medical device testing, clinical research, and regulatory consulting company.
Sources: en.wikipedia.org
A hangover is the experience of various unpleasant physiological and psychological effects usually following the consumption of alcohol, such as wine, beer, and liquor. Hangovers can last for several hours or for more than 24 hours. Typical symptoms of a hangover may include headache, drowsiness, concentration problems, dry mouth, dizziness, fatigue, gastrointestinal distress (e.g., nausea, vomiting, diarrhea), absence of hunger, light sensitivity, depression, sweating, hyper-excitability, irritability, and anxiety (often referred to as "hangxiety").
== Veterinary use == BCG is used in England by licensed individuals to vaccinate wild badgers by trapping and release. It reduces new bovine TB infection rates by up to 76% in vaccinated badgers. It also exhibits a herd immunity effect, where a badger social group with more than one-third vaccination coverage shows up to 79% lower new infection in cubs. There is no evidence that vaccinated badgers excrete live BCG into the environment. Vaccination initiatives have been lead both by the government's Animal and Plant Health Agency and by private individuals and groups such as farmers seeking to protect their livestock and landowners seeking to clear their land of TB. BCG vaccination in cattle has completed a phase II trial in the UK with satisfactory results. The phase III trial started in 2025.
Abuse of fenethylline using the former brand name Captagon is common in the Middle East, and counterfeit versions of the drug continue to be available despite its illegality. Fenethylline is much less common outside of the Middle East, to the point that police may not recognize the drug. Fenethylline production and export were a significant industry sponsored by Bashar al-Assad's government, with revenue from its exports contributing more than 90% of its foreign currency. After the fall of al-Assad's government in Syria, Captagon trade fell by around 90%. The Assad regime's annual fenethylline revenues were estimated to have been worth US$57 billion in 2022, about three times the total trade of the entire Mexican illicit drug market. Later research demonstrated that this assistance, largely the financing of production and sponsoring networks of drug dealers, was undertaken through the former Assad regime's Military Intelligence Directorate (Syria). In July 2019 in Lebanon, captagon was sold for $1.50 to $2.00 a pill. In 2021 in Syria, low-quality pills were sold locally for less than $1, while high-quality pills are increasingly smuggled abroad and may cost upwards of $14 each in Saudi Arabia. Many of these counterfeit "Captagon" tablets contain other amphetamine derivatives that are easier to produce, but are pressed and stamped to look like Captagon pills. Some counterfeit Captagon pills analysed do contain fenethylline, indicating that illicit production of the drug continues to take place.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.